HC Wainwright & Co. analyst Michael King maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from $43 to $46.
Cisco Continues Its Startup Acquisition Journey Despite Cost Challenges
The networking hardware maker reported earnings last week, with earnings coming in better than expected but guidance came in slightly below what analysts had expected.
